Cigna Group (NYSE: CI) shares are trading higher after the company reportedly ended its attempt to negotiate an acquisition deal with rival Humana Inc (NYSE: HUM) after the pair
Alzamend Neuro Inc (NASDAQ: ALZN) received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for
Biomea Fusion Inc (NASDAQ: BMEA) announced the poster presentation of long-term 26 weeks follow-up data from the first two cohorts of adults with type 2 diabetes (T2D) enrolled in the ongoing Phase 2 study (COVALENT-111) and data from preclinical ex-vivo
eFFECTOR Therapeutics Inc (NASDAQ: EFTR) announced new interim data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 study of zotatifin in patients with estrogen receptor positive (ER+)
Intensity Therapeutics Inc (NASDAQ: INTS) announced that safety, tolerability, efficacy, and immune activation data from its Phase 2 INVINCIBLE trial of INT230-6 in patients with early-stage breast cancer without chemotherapy was presented during the 2023 San Antonio